XELOX方案与mFOLFOX6方案一线治疗结直肠癌的临床效果观察

来源:用户上传      作者:陈方

　　[摘要] 目的 分析对比结直肠癌一线治疗过程中应用XELOX方案与mFOLFOX6方案的临床效果。方法 随机选择2018年1月至2020年6月因结直肠癌来徐州医科大学附属沭阳医院接受一线治疗的患者作为研究对象，共计72例，通过系统随机分组的方式将其平均分入XELOX组（n=36，应用XELOX方案治疗）与mFOLFOX6组（n=36，应用mFOLFOX6方案治疗），比较两组的治疗效果。结果 治疗后，XELOX组的临床总疗效、各项生存质量评分结果均与mFOLFOX6组无显著差异（P>0.05）;XELOX组不良反应以恶心呕吐、白细胞降低、手足综合征为主，其中手足综合征发生率相较mFOLFOX6组略有升高，差异有统计学意义（P<0.05），但以Ⅰ～Ⅱ度为主，mFOLFOX6组周围神经毒性发生率显著较XELOX组更高，手足综合征更低，差异有统计学意义（P<0.05），同右寓瘛Ⅱ度为主。两组的其他不良反应发生率比较，差异无统计学意义（P>0.05）。但XELOX组Ⅲ～Ⅳ度少于mFOLFOX6组，其安全性更好。结论 XELOX方案和mFOLFOX6方案均能在结直肠癌一线治疗中发挥良好的诊治效果，但前者不良反应严重程度相对更轻，更具诊疗优势。
　　[关键词] 结直肠癌;XELOX方案;mFOLFOX6方案;生存质量;一线治疗;不良反应
　　[中图分类号] R735.3 [文献标识码] B [文章编号] 1673-9701（2022）13-0075-04
　　[Abstract] Objective To analyze and compare the clinical effect of XELOX regimen and mFOLFOX6 regimen in the first-line treatment of colorectal cancer. Methods A total of 72 patients with colorectal cancer who received first-line treatment in the Affiliated Shuyang Hospital of Xuzhou Medical University from January 2018 to June 2020 were randomly selected as the study subjects and equally divided into XELOX group （n=36， treated with XELOX regimen） and mFOLFOX6 group （n=36， treated with mFOLFOX6 regimen） by systematic randomization. The therapeutic effects were compared between the two groups. Results After treatment， there was no significant difference in the overall clinical efficacy and various quality of life scores between the XELOX group and the mFOLFOX6 group （P>0.05）. The adverse reactions in the XELOX group were mainly nausea and vomiting， leukopenia， and hand-foot syndrome， of which the incidence of hand-foot syndrome was slightly higher than that in the mFOLFOX6 group. The difference was statistically significant （P<0.05）. However， grade Ⅰ-Ⅱ was predominant. The incidence of peripheral neurotoxicity was significantly higher， and hand-foot syndrome in the mFOLFOX6 group was lower than in the XELOX group， with a statistically significant difference （P<0.05）， which were also mainly grade Ⅰ-Ⅱ. There was no significant difference in the incidence of other adverse reactions between the two groups （P>0.05）. However， the XELOX group had less grade Ⅲ-Ⅳ than the mFOLFOX6 group， which had better safety. Conclusion Both the XELOX regimen and mFOLFOX6 regimen can play a good role in the diagnosis and treatment of colorectal cancer in first-line treatment. However， the former has relatively milder adverse reactions and more advantages in diagnosis and treatment.

nlc202206161020

转载注明来源:https://www.xzbu.com/6/view-15433743.htm